Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label post-marketing study of opicapone (Ongentys) in Parkinson's disease with wearing-off
2016-002391-27Phase 4Completed
- Sponsor
- BIAL
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of opicapone in Parkinson's disease (PD), sponsored by BIAL. Primary endpoint: Investigator's Global Assessment of Change at Visit 4. Started Aug 2016; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-002391-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002391-27.